Table 1 Serological and NAAT analysis
From: Rubella virus-associated uveitis at a tertiary care hospital in Germany between 2013 and 2019
Rubella | VZV | HSV | CMV | Toxoplasma | |||
|---|---|---|---|---|---|---|---|
seroprevalence | [%(n/total)] | 94.7 (151/159) | 98.7 (157/159) | 82.4 (131/159) | 61.6 (98/159) | 69.2 (110/159) | |
intraocular antibody prevalence | [% (n/total)] | 62.9 (100/159) | 62.3 (99/159) | 64.8 (103/159) | 42.1 (67/159) | 39.6 (63/159) | |
Goldmann-Witmer coefficient ≥ 2 | [% (n/total)] | 24.5 (39/159) | 6.3 (10/159) | 5 (8/159) | 1.9 (3/159) | 3.1 (5/159) | |
monocular | [% (n/total)] | 92.3 (36/39) | 90 (9/10) | 100 (8/8) | 66.6 (2/3) | 80 (4/5) | |
binocular | [% (n/total)] | 7.7 (339) | 10 (1/10) | 0 (0/8) | 33.3 (1/3) | 20 (1/5) | |
Serum IgM reactivity | [% (n/total)] | 12.8 (5/39) | 0 (0/10) | 0 (0/8) | 0 (3/3) | 0 (5/5) | |
Serum IgG avidity below 30% | [% (n/total)] | 0 (0/39) | 0 (0/10) | 0 (0/8) | 0 (3/3) | 0 (5/5) | |
positive NAAT | [% (n/total)] | 0 (0/30) | 40 (2/5) | 66.6 (2/3) | 33.3 (1/3) | 50 (1/2) | |